Studies using tumor models have also shown some reduction in angiogenesis by pharmaceutically targeting SphK1, but these studies contradict one another and are further complicated by the role that S1P plays in tumor cell growth and proliferation [35,67,68,69]. This evidence concerns the gene SPHK1 and neoplasm.